Prostate Cancer - Results from #1420

Genomic Correlates of Prostate-Specific Membrane Antigen Expression and Response to 177Lu-PSMA-617: A Retrospective Multicenter Cohort Study. April 29, 2024

Prospective Comparison of 68Ga-NeoB and 68Ga-PSMA-R2 PET/MRI in Patients with Biochemically Recurrent Prostate Cancer. April 29, 2024

Activity of Lutetium-177 Prostate-specific Membrane Antigen and Determinants of Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Cabazitaxel: The PACAP Study. April 29, 2024

The State of Intermediate Clinical Endpoints as Surrogates for Overall Survival in Prostate Cancer in 2024. April 29, 2024

Randomized Trial of Prostate-Specific Membrane Antigen PET/CT Before Definitive Radiotherapy for Unfavorable Intermediate- and High-Risk Prostate Cancer (PSMA-dRT Trial). April 29, 2024

Diagnostic Performance and Safety of 18F-rhPSMA-7.3 Positron Emission Tomography in Men With Suspected Prostate Cancer Recurrence: Results From a Phase 3, Prospective, Multicenter Study (SPOTLIGHT). Letter. April 27, 2024

Cancer-associated fibroblasts promote enzalutamide resistance and PD-L1 expression in prostate cancer through CCL5-CCR5 paracrine axis. April 26, 2024

Zeb1-controlled metabolic plasticity enables remodeling of chromatin accessibility in the development of neuroendocrine prostate cancer. April 26, 2024

Prostate-specific Membrane Antigen: Alpha-labeled Radiopharmaceuticals. April 26, 2024

AZGP1 deficiency promotes angiogenesis in prostate cancer. April 26, 2024

Part I: prostate cancer detection, artificial intelligence for prostate cancer and how we measure diagnostic performance: a comprehensive review. April 26, 2024

Ultrasensitive PSA: rethinking post-surgical management for node positive prostate cancer. April 26, 2024

Molecular analysis of archival diagnostic prostate cancer biopsies identifies genomic similarities in cases with progression post-radiotherapy, and those with de novo metastatic disease. April 26, 2024

Limited prognostic role of routine serum markers (AP, CEA, LDH and NSE) in oligorecurrent prostate cancer patients undergoing PSMA-radioguided surgery. April 26, 2024

Astellas’ XTANDI (Enzalutamide) Granted European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting April 25, 2024

The impact of telomere length on prostate cancer aggressiveness, genomic instability and health disparities. April 25, 2024

Prostate cancer knowledge and barriers to screening among men at risk in northern Tanzania: A community-based study. April 25, 2024

FOXA1 regulates ribosomal RNA transcription in prostate cancer. April 25, 2024

Biomarker vs MRI-Enhanced Strategies for Prostate Cancer Screening: The STHLM3-MRI Randomized Clinical Trial. April 25, 2024

Reducing False-Positives Due to Urinary Stagnation in the Prostatic Urethra on 18F-DCFPyL PSMA PET/CT With MRI. April 25, 2024

Page 72 of 1458